ABSTRACT Introduction: To provide information for cervical cancer screening and vaccination in Henan province, China, the distribution of human papillomavirus (HPV) was analyzed. Methods: The HPV genotypes were detected using gene array and flowthrough hybridization. Results: Overall, 38.1% (1,536/4,033) of the women were human papillomavirus deoxyribonucleic acid (HPV DNA) positive. The prevalence of high-risk HPV types was 32.4%. HPV 16 was the most prevalent genotype (8.9%), followed by HPV 52 (5.8%) and HPV 58 (4.4%). Conclusions: The data support close surveillance of women for cervical cancer screening, and HPV prophylactic vaccines including HPV16, HPV 52, and HPV 58 might offer greater protection in this area.
Cervical cancer is the third most common cancer and fourth leading cause of mortality among women worldwide (1) , with more than 85% of the cases occurring in developing countries such as China (2) . Evidence indicates that a large proportion of cervical cancer can be prevented through organized cervical screening (3) .
Because human papilloma virus (HPV) causes almost all cervical cancers (4) , human papillomavirus deoxyribonucleic acid (HPV DNA) testing would be appropriate to objectively screen cervical cancer, with high sensitivity and specificity. More than 200 different HPV genotypes have been identified to date, and approximately 40 oncogenic subtypes are associated with the majority of cases of cervical cancer (5) . Based on their association with cervical cancer, HPV genotypes can be classified into highrisk (HR) HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) or low-risk (LR) HPV (HPV 6, 11, 40, 42, 43, and 44) (5) . In particular, HPV 16 and HPV 18 collectively account for 70% of cervical cancers worldwide (6) . To some extent, the detection of HR-HPV may reduce the risk of developing cervical cancer and associated deaths (7) , and understanding the HPV genotype distribution would aid with the design of HPV vaccines for cervical cancer prevention.
Here, we investigated cervical HPV infections in the general female population in Henan province, located in central China, to determine the overall and type-specific HPV prevalences, using the commercially available HPV DNA Array.
From January 2014 to August 2014, 4,033 consecutive samples of exfoliated cervical cells from women attending the gynecological outpatient clinic were collected in the First Affiliated Hospital of Zhengzhou University, China. Eligible women included those who were not a virgin, were not presently pregnant, were not presently menstruating, had not had sexual intercourse within seven days, had not undergone a total hysterectomy, had not used vaginal medication in the previous 48 hours, had no history and associated symptoms of other HPV-related diseases, and were willing to undergo HPV testing. All participants agreed to participate in the present study, and the study project was approved by the ethical committee of the First Affiliated Hospital of Zhengzhou University.
Samples of exfoliated cervical cells were collected for HPV genoarray testing according to the manufacturer's instructions (Yaneng Biotechnology Corp., Shenzhen, China). All data were analyzed using Statistical Package for the Social Sciences (SPSS) version 16.0 (SPSS Corp., Chicago, IL, USA). The χ 2 test was used to assess the statistical significance of any differences in prevalence. A significance level of 0.05 was used.
The median age of the participating women was 40 years (16-87 years). Of the 4,033 samples, no sample was lost, as the control was normal in all tests. Overall, 1,536 (38.1%) women were HPV-positive for any HPV DNA, 32.4% (1,308/4,033) had an HR-HPV infection, which was higher than the 12.6% (510/4,033) that had an LR-HPV infection ( ( Table 1) . As shown in Figure 1 , there were two peaks of HPV infection based on age: the first was for women aged <21 years, of whom 55.6% were infected, and the second was for women aged 66-70 years, of whom 48% were infected (p = 0.003). Similar patterns of two peaks were also observed for HR-HPV infections (p = 0.028) and LR-HPV infections (p < 0.001), with the first peaks for both types of infection for women aged <21 years (48.1% and 29.6%, respectively). However, the second peak for HR-HPV infection was for women aged 56-60 years, of whom 42.5% were infected, and the second peak for LR-HPV infection was for women aged 61-65 years, of whom 25% were infected. The prevalences of multiple types of HPV infections were significantly different among the age groups (p < 0.001), while the prevalences of a single type of HPV infection were relatively constant across the age groups (p = 0.930) (Figure 1 ). Among the women infected with multiple types of HPV, the first peak (29.6%) was for those aged <21 years old, and the second peak (25.8%) was for those aged 66-70 years (p < 0.001). The prevalence of HPV 16 or HPV 18 did not differ across the age groups (data not shown).
A single type of HPV infection was detected in 24.2% (977/4,033) of the entire sample, and multiple types of HPV infections were detected in 13.9% (559/4,033) of the entire sample (Table 2 ). In the group of women with a single type of infection-, HPV 16 was the most prevalent (18.9%, 185/977), followed by HPV 52 (10.3%, 101/977), HPV 58 (8.1%, 79/977), HPV 53 (6.7%, 65/977), and HPV 6 (5.9%, 58/977). In the group of women with multiple types of infection-, the most prevalent genotype was HPV 16 (30.8%, 172/559), followed by HPV 52 (24%, 134/559), HPV 58 (17.4%, 97/559), HPV 53 (17.2%, 96/559), and HPV 81 (16.1%, 90/559) ( Table 2 ).
In the present study, the most prevalent HPV genotype was HPV 16, followed by HPV 52 and HPV 58 (Table 1) , which was similar to the findings of a previous study of the prevalence of HPV infection in Henan province (8) . However, in another study conducted in this area, the most prevalent HPV genotype was HPV 16 (9.2%, 53/578), followed by HPV 52 (7.8%, 45/578) and HPV 6 (6.9%, 40/578) (9) . As the biggest hospital in the center of China, clinical data from the First Affiliated Hospital of Zhenghou University might be more representative of the population. In other areas, such as in the North (10) , South (11) , and Southeast (12) of China, the most commonly detected HPV types were also different. These differences may be due to the geographical and biological interplay between HPV types or variants and host immunogenic factors, as previously described (13) .
Compared with Shenzhen and Shanghai City (13.8% and 30.2%, respectively) (11) (13) , a higher (38.1%) prevalence of HPV infection was observed in the present study. The first peak of HPV infection occurred for women aged <21 years (55.6%), which might be related with a lack of adaptive immune responses and susceptibility to HPV infection (12) . The second peak was observed for women aged 66-70 years (48.4%); this age group also had the most cervical cancer patients (data not shown). It is possible that latent HPV in the body was reactivated owing to physiologic and immunologic dysregulation caused by hormonal fluctuations during the transition to menopause (13) ( Figure 1) . However, the reasons for the decrease in HPV infection prevalence in women aged >70 years requires further investigation.
Most HPV infections are transient and might resolve spontaneously; however, persistent infections with a subset of HPV genotypes are necessary to develop cervical cancer and its precursors. In the present study, the different peaks of HPV infection were observed in those aged 50-70 years; therefore, women who are first infected with HR-HPV at 56-60 years of age and do not receive appropriate treatment might become infected with LR-HPV at 61-65 years and finally develop multiple types of HPV infection at 66-70 years (Figure 1 ). When compared with women with a single infection, women infected with multiple types of HPV are at a significantly higher risk of both cervical intraepithelial neoplasia grade 2 and high-grade squamous intraepithelial lesions (14) . Unfortunately, in the present study, cervical cytology and cancer state were missing for the samples. Therefore, further analysis is needed. HPV vaccination could decrease the incidence of HPVrelated cancers, as well as reduce the burden associated with the treatment of HPV-related benign lesions (15) . Our findings indicate that the trivalent vaccine (targeted at HPV 16, HPV 52, and HPV 58) would provide good efficacy in the central area of China, because the three most prevalent HPV genotypes in this area were HPV 16, HPV 52, and HPV 58 (Table 1) . In summary, increasing women's awareness of the relationship between HPV infection and cervical cancer is the most important recommendation. The prevalence of HPV infection in the central area of China was 38.1%, and the most common genotypes were HPV 16 (18.9%), HPV 52 (10.3%), and HPV 58 (8.1%). Our data support close surveillance of women aged <21 years or >55 years for cervical cancer screening. Furthermore, our findings support the hypothesis that the next-generation HPV prophylactic vaccines that include HPV 52 and HPV 58 might offer greater protection for women in this area.
